Medication topics
Guselkumab articles covering Tremfya, IL-23 therapy, trial evidence, approvals, safety, and IBD treatment decisions. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
Page 1 of 3 · 99 articles
The updated official label affects dosing options, monitoring, and safety information for guselkumab in people with Crohn’s disease and ulcerative colitis, which can influence treatment decisions and routine testing.
Long-term Phase 3 extension data suggest guselkumab (Tremfya) can sustain clinical and endoscopic remission through three years for some patients with Crohn’s disease.
Perianal fistulas are a challenging complication of Crohn’s disease with limited effective options; a phase 3 trial reports that guselkumab improved fistula remission rates through 48 weeks, which could offer a new...
New Phase III data on guselkumab are directly relevant because they report long-term (3-year) maintenance results for Crohn’s disease and one-year fistula outcomes for people with perianal disease — areas that affect...
Cure8 could only read part of this source from finance.yahoo.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.
Narrowing (stenosis) can cause obstructive symptoms and often leads to surgery; evidence that a biologic—guselkumab—may improve non-passable stenosis and reduce fibrosis-associated biology could affect treatment planning...
Perianal fistulas are a common, debilitating complication of Crohn’s disease; longer-term data on treatments that can produce durable fistula remission are directly relevant to patients and clinicians managing this...
These Phase 3 results suggest guselkumab (TREMFYA) may provide durable clinical and endoscopic benefit through three years for adults with moderate to severe Crohn’s disease and may help with perianal fistula...
Phase III AFFIRM results suggest a subcutaneous risankizumab regimen may increase endoscopic remission in Crohn’s disease, which matters for patients and clinicians weighing biologic options and for regulatory approval...
The analysis helps compare multiple advanced therapies when head‑to‑head trials are lacking, which may inform drug selection for induction and maintenance in moderate‑to‑severe UC, including for patients who have failed...
Long-term Phase 3 extension data suggest guselkumab (Tremfya) may provide sustained clinical and endoscopic remission for some adults with moderate-to-severe Crohn's disease, which could expand treatment options for...
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from seekingalpha.com.
Long-term control of symptoms and intestinal inflammation is a major need in Crohn's disease. Three-year data showing sustained clinical and endoscopic remission and high rates of steroid-free remission could be...
Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.
Long-term (3-year) data on a biologic for Crohn's disease may indicate how durable treatment benefits and steroid-free remission can be for people considering or already on biologic therapy.
Perianal fistulas are a common and debilitating complication of Crohn’s disease that often need medical and surgical care. A Phase 3 trial reporting improved fistula remission with an IL-23–targeting therapy could offer...
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...
Perianal fistulas cause significant morbidity and often need both medical and surgical treatments. Newer drug options and updated guideline support earlier use of advanced therapies, which may improve healing and reduce...
Perianal fistulizing Crohn's often causes significant symptoms and requires both medical and surgical approaches. Newer biologics and JAK inhibitors expand treatment options and guidelines increasingly support earlier...
This registry will collect real-world data on guselkumab use in adults with moderate-to-severe Crohn's disease or ulcerative colitis, focusing on how long patients stay on treatment, effectiveness in routine practice,...
A single‑patient report suggests guselkumab (IL‑23 inhibitor) may control both refractory pyoderma gangrenosum and coexisting Crohn disease when several prior treatments failed.
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...
IL-23 inhibitors are a newer class of biologics for moderate-to-severe ulcerative colitis that may offer another effective option for patients who have not responded to existing therapies, with improving evidence for...
PG is a serious skin complication that can occur with UC. This report suggests guselkumab—an IL‑23 blocker used in IBD and dermatology—helped resolve PG in one patient without loss of UC remission, which could be...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease, Guselkumab, and IL-23 inhibitor. The original article is from Journal of clinical...
Knowing biomarkers that predict who will respond to IL23 p19 inhibitors could help people with IBD avoid trial-and-error therapy choices. Understanding whether increasing risankizumab dosing after loss of response...
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
A new IL-17A drug (vunakizumab) is reported to have triggered severe ulcerative colitis in one patient, suggesting clinicians and patients starting IL-17A inhibitors should watch for early gastrointestinal symptoms.
People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...
Phase 3 testing of guselkumab (an IL-23–targeting biologic) in moderately to severely active ulcerative colitis could expand treatment options if the trial meets its endpoints and shows an acceptable safety profile. The...
Pharmacokinetics affect how well biologic drugs work for IBD. Better PK data could help explain why many patients have inadequate responses and could inform personalized dosing for IL-23p19 inhibitors used in Crohn’s...
Researchers are testing whether targeting fungi with fluconazole can boost how well IL-23 biologics work for Crohn’s disease — if positive, this could point to a new adjunctive strategy to improve responses to biologic...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from Journal of Crohn's & colitis.
Children with IBD often wait years for medicines to be approved after adult approvals; this review shows many ongoing paediatric trials for biologics and small molecules that could improve treatment options.
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.
People with moderate-to-severe Crohn's disease or ulcerative colitis and their clinicians may want to know how long patients stay on guselkumab in real-world care, since persistence reflects tolerability, benefit, and...
This registered Phase 2/3 program is evaluating guselkumab (an IL‑23 inhibitor) for moderate–severe Crohn's disease and could expand treatment options if trials show benefit and safety. The studies include clinical and...
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
This trial could provide long-term safety data on guselkumab for children with moderate-to-severe Crohn's disease or ulcerative colitis and offers continued access to the drug for participants from earlier pediatric...
A Phase 3 trial is testing whether guselkumab can produce MRI-detected transmural healing in Crohn's disease — an outcome that could reflect deeper intestinal healing than symptom improvement alone. If successful, it may...
People with IBD who are breastfeeding and are taking guselkumab may want data on how much of the drug gets into breast milk and the estimated infant exposure. This study aims to provide those measurements for the Q4W and...
This Phase 3 trial directly compares two IL-23–targeting biologic therapies in moderate-to-severe Crohn's disease with a 52-week deep remission endpoint, which could inform future treatment choices if results are...
This registered Phase 2 trial tests guselkumab, golimumab, and a new investigational agent (JNJ-78934804) in adults with moderate–severe ulcerative colitis who previously failed advanced therapies. Results could affect...
Real-world data may help show how guselkumab performs in routine clinical practice for adults with moderate-to-severe UC who haven’t had prior biologics, information that could be useful to patients and clinicians...
A new IL-23–targeting therapy (JNJ-78934804) is being tested against an approved IL-23 inhibitor (guselkumab) in a large Phase 3 trial for moderate–severe ulcerative colitis, which could affect future treatment options...
A Phase 2/3 trial of guselkumab could expand biologic treatment options for people with moderate to severe ulcerative colitis if efficacy and safety are demonstrated. The trial’s use of standard clinical endpoints...
A successful Phase 3 trial could add guselkumab — an IL-23–targeting biologic — as a treatment option for people with moderate to severe Crohn's disease, especially those who haven’t responded to prior therapies.
Extrapulmonary TB can be triggered or revealed during immunosuppressive biologic therapy and may mimic other causes of liver injury; early recognition and TB-specific testing are important for timely treatment and to...
